Diabetes patients who used lixisenatide as an add-on to basal insulin had lower A1C, body weight and self-measured blood glucose profiles than those in the placebo arm, researchers reported at the European Association for the Study of Diabetes meeting. Patients with baseline fasting plasma glucose of less than 6.7 mmol/L showed greater placebo-adjusted improvements compared with those who had higher fasting glucose levels, researchers added.

Related Summaries